Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Gefit inib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia and the presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib.
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
- W. Travis, E. Brambilla, David Yankelewitz
- MedicineJournal of thoracic oncology : official…
- 1 February 2011
This new adenocarcinoma classification is needed to provide uniform terminology and diagnostic criteria, especially for bronchioloalveolar carcinoma (BAC), the overall approach to small nonresection cancer specimens, and for multidisciplinary strategic management of tissue for molecular and immunohistochemical studies.
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with…
- M. Fukuoka, Yi-long Wu, T. Mok
- Biology, MedicineJournal of clinical oncology : official journal…
- 20 July 2011
EGFR mutations are the strongest predictive biomarker for PFS and tumor response to first-line gefitinib versus carboplatin/paclitaxel and the predictive value of EGFR gene copy number was driven by coexisting EGFR mutation (post hoc analysis).
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.
Irinotecan plus cisplatin is an effective treatment for metastatic small-cell lung cancer and severe or life-threatening diarrhea was more frequent in the irinotican-plus-cisplatin group than in the etoposide-plus -cis Platin group.
Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology…
This study strongly suggests that cisplatin plus etoposide and concurrent radiotherapy is more effective for the treatment of LS-SCLC than cisPlatin plus Etoposid and sequential radiotherapy.
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.
- R. Maruyama, Y. Nishiwaki, M. Fukuoka
- Medicine, BiologyJournal of clinical oncology : official journal…
- 10 September 2008
Gefitinib significantly improved objective response rate and quality of life versus docetaxel; progression-free survival, disease control rates, and symptom improvement were similar for the two treatments.
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer:…
- Y. Ohe, Y. Ohashi, M. Fukuoka
- Biology, MedicineAnnals of oncology : official journal of the…
- 1 November 2006
Four platinum-based combination regimens against cisplatin plus irinotecan have similar efficacy and different toxicity profiles, and they can be used to treat advanced NSCLC patients.
Highly Sensitive Detection of EGFR T790M Mutation Using Colony Hybridization Predicts Favorable Prognosis of Patients with Lung Cancer Harboring Activating EGFR Mutation
- Y. Fujita, K. Suda, K. Nishio
- Biology, MedicineJournal of thoracic oncology : official…
- 1 November 2012
A subgroup of non–small-cell lung cancer patients with the EGFR mutation harbored the rare T790M allele before EGFR-TKI treatment, which may define a clinical subset with a relatively favorable prognosis.